Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Ana Lako et al.|JAMA Oncology|2020Cited by 350
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumorsJason J. Luke, Stéphane Champiat, David J. Pinato et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 34